EMA Authorised: Gotenfia (golimumab) — Stada Arzneimittel AG

View source ↗

Summary

The EMA authorised Gotenfia (golimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Juvenile Idiopathic Arthritis
• Non-radiographic Axial Spondyloarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Gotenfia (golimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile;Arthritis, Psoriatic;Axial Spondyloarthritis;Non-Radiographic Axial Spondyloarthritis;Colitis, Ulcerative. MAH: Stada Arzneimittel AG. Decision date: 10/02/2026